Johnson & Johnson says CARVYKTI delivered five-year remissions
Johnson & Johnson said a single infusion of CARVYKTI delivered five-year treatment-free remissions in 50% of patients with early-line relapsed/refractory multiple myeloma.
Johnson & Johnson said a single infusion of CARVYKTI delivered five-year treatment-free remissions in 50% of patients with early-line relapsed/refractory multiple myeloma.